Cue Biopharma Inc stock (US22966J1060): Nasdaq-listed immunotherapy developer after reverse split and recent quarterly update

Cue Biopharma Inc is back on the radar of biotech-focused investors after corporate actions and recent financial updates, with the United States-based immunotherapy developer continuing to trade on Nasdaq under the ticker CUE at a relatively low absolute share price following a 1-for-30 reverse stock split in early 2024.

According to Robinhood's corporate actions tracker, Cue Biopharma implemented a 1-for-30 reverse split of its common stock, meaning shareholders received 1 new CUE share for every 30 shares previously held, an action that is recorded as having taken effect in 2024 to support the stock's continued listing on Nasdaq.Robinhood as of 2024

As a Nasdaq-listed security in the United States, Cue Biopharma's home market hook is clear, with the primary listing on Nasdaq in New York and trading in US dollars, while German investors also access the stock via secondary venues such as Tradegate and Frankfurt where it is quoted in euros alongside its home-market line.

The stock continues to show notable volatility typical for small-cap clinical-stage biotechnology names, with recent price data from Wallstreet Online indicating that the Cue Biopharma share recorded a 52-week high of 26.08 EUR on the German market with a prior-day close of 22.78 EUR as of 06/04/2026, underlining the amplitude of moves in this niche segment.Wallstreet Online as of 06/04/2026

Per the same Wallstreet Online snapshot, the site also reports a Cue Biopharma real-time quote of 20.435 USD at 02:00:00 on 06/04/2026, illustrating the linkage between the euro-denominated trading on German platforms and the underlying US listing that sets the primary price discovery for the stock.Wallstreet Online as of 06/04/2026

From a company perspective, Cue Biopharma positions itself as a clinical-stage therapeutics enterprise focused on immunotherapies, with its official investor relations materials emphasizing a pipeline of potentially transformative therapies aimed at modulating the immune system for the treatment of cancer and other diseases, and these details are regularly updated via its corporate website.Cue Biopharma IR as of 2026

The reverse split and the ongoing trading pattern provide the immediate hook for investors monitoring the stock, especially against the backdrop of quarterly reporting and funding conditions in the US biotech sector, where many early-stage companies seek to keep their share price above minimum exchange thresholds while continuing to finance research and development.

As of: 06/05/2026

By the editorial team - specialized in equity coverage.

Cue Biopharma Inc: core business model

Cue Biopharma develops targeted immunotherapies using its proprietary protein engineering platforms to selectively engage and modulate disease-relevant immune cells, generating revenue primarily through research collaborations and licensing deals linked to its oncology-focused pipeline.

Valuation metrics and multiples for Cue Biopharma Inc

On Fridays, valuation aspects often come into focus for investors reviewing their weekly portfolio positioning, and in the case of Cue Biopharma the discussion centers less on traditional earnings multiples and more on market capitalization relative to its clinical pipeline and partnership potential, a common pattern among pre-revenue or early-revenue biotechnology companies.

Public data collated by services such as Zacks show that analysts tracking Cue Biopharma have historically framed the valuation using price targets that serve as a proxy for perceived risk-reward rather than relying on conventional ratios like price-earnings, with one Zacks research page indicating an average short-term price target of USD 4.00 for CUE shares based on a small sample of analyst opinions, though investors should note that these aggregation figures can lag company developments and should be cross-checked against the latest filings and news.Zacks as of 2026

Given that Cue Biopharma remains loss-making at the clinical-development stage and continues to invest in trials and preclinical research, traditional valuation ratios such as price-earnings or EV/EBITDA are typically not meaningful, so investors instead tend to benchmark the company against other small-cap immuno-oncology developers by comparing market values, cash positions and the breadth and stage distribution of product candidates as disclosed in recent quarterly updates and investor presentations.

In this context, the absolute share price level following the 1-for-30 reverse split, the reported 52-week high in euro terms on German venues, and the analyst aggregation datasets from Zacks and others form part of a broader mosaic that market participants use to gauge whether Cue Biopharma trades at a discount or premium to comparable US-listed biotech peers.

Conclusion

Cue Biopharma Inc remains an actively traded, Nasdaq-listed US biotechnology stock, with the 1-for-30 reverse split in 2024 and the current 52-week high of 26.08 EUR on German venues highlighting both corporate actions and volatility that matter for investors tracking the name.

With traditional valuation metrics offering limited guidance due to its clinical-stage and loss-making status, many market participants focus on the relationship between Cue Biopharma's market capitalization, analyst-derived price targets on platforms such as Zacks, and the progress reported in investor updates about its immunotherapy pipeline.

The stock therefore continues to appeal primarily to risk-tolerant biotech specialists who closely follow regulatory milestones, trial readouts and funding developments and who are prepared to navigate the pronounced share-price swings that often accompany micro-cap immuno-oncology names on Nasdaq and secondary trading venues.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.